Hematology

New research establishes a strong causal link between elevated 25(OH)D levels and a reduced risk of anemia.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

Pre-pregnancy overweight and obesity were not linked to an increased prevalence of iron deficiency or anemia during pregnancy in a US population.

A real-world post-authorization safety study identified no new safety signals compared with the phase 2/3 clinical trial of rpFVIII for acquired hemophilia A.

An investigation into basic and instrumental activities of daily living in older female patients found greater reliance in those with anemia.

A systematic review found a higher prevalence of acute pancreatitis in individuals with the HbSS genotype, though a meta-analysis could not be performed.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

This August 2024 month in review highlights new recommendations from the USPSTF, FDA approval of a treatment for chronic GVHD, and Phase 2 data for severe HDFN.

Moderate to severe anemia was linked to an increase in cardiac arrest or stroke compared with normal hemoglobin levels in critically ill COVID-19 patients.

Across a statewide cohort, more than half of patients were unable to achieve iron deficiency resolution within 3 years.

A new recommendation statement cites a lack of current evidence to assess the benefits of iron deficiency screening and supplementation in pregnant individuals.

A randomized clinical trial found significant improvements in key blood parameters for anemia after grape syrup intervention compared with placebo.

Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.

Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

Interim analysis of STELLAR showed health-related quality of life domains were within a normal range after hematopoietic cell transplant for SCD.

Nipocalimab led to a substantially higher percentage of live births at 32 weeks’ gestation or later without intrauterine transfusions than the historical benchmark.

Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses.

Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.

Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.

Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk.

Our July 2024 hematology month in review examines the latest updates to the hematological pipeline and key study data informing clinical practice.

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.